Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BRX5

UPID:
PSF3_HUMAN

ALTERNATIVE NAMES:
GINS complex subunit 3

ALTERNATIVE UPACC:
Q9BRX5; B2RDP3; E9PB21; Q9H870

BACKGROUND:
GINS complex subunit 3, also known as DNA replication complex GINS protein PSF3, plays a critical role in DNA replication. As a core component of the GINS complex, it is essential for the correct functioning of the CMG helicase, facilitating the unwinding of DNA. This process is fundamental for the accurate duplication of the genome, a prerequisite for cell division.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of GINS complex subunit 3 offers a promising avenue for therapeutic intervention. Given its essential role in DNA replication, targeting this protein could lead to innovative strategies for managing diseases characterized by abnormal cell growth.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.